Catalyst Pharmaceutical Partners (NASDAQ:CPRX) COO Steve Miller purchased 100,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, June 4th. The shares were purchased at an average cost of $2.17 per share, for a total transaction of $217,000.00. Following the transaction, the chief operating officer now directly owns 214,754 shares in the company, valued at approximately $466,016. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded up 1.41% during mid-day trading on Wednesday, hitting $2.16. 487,507 shares of the company’s stock traded hands. Catalyst Pharmaceutical Partners has a 52 week low of $0.83 and a 52 week high of $3.65. The stock has a 50-day moving average of $1.97 and a 200-day moving average of $2.0. The company’s market cap is $145.1 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last announced its earnings results on Friday, May 16th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.01. On average, analysts predict that Catalyst Pharmaceutical Partners will post $-0.27 earnings per share for the current fiscal year.
CPRX has been the subject of a number of recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Catalyst Pharmaceutical Partners in a research note on Monday, April 14th. They set an “overweight” rating and a $4.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Catalyst Pharmaceutical Partners in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Catalyst Pharmaceutical Partners presently has a consensus rating of “Buy” and an average target price of $3.41.
Catalyst Pharmaceutical Partners, Inc is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.